Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 13-valent pneumococcal conjugate vaccine in at-risk Japanese subjects aged 6 to 64 years
2018-003054-24Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoint: Local reactions within 7 days after vaccination in subjects aged 6 to under 18 years.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-003054-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003054-24.